Quick Verdict
ZakatInvest classifies AbbVie (ABBV) as doubtful. Developing medicines for serious diseases is generally beneficial and permissible. However, AbbVie's March 2026 interest-bearing debt equals 53.39% of total assets, above every total-assets limit examined below. Its product-level formulations, biologic inputs, cell lines, research methods, licensing, and use-specific aesthetics revenue are not disclosed as a Sharia-screened numerator, so the qualitative business calculation remains incomplete.
What AbbVie's Business Includes
AbbVie is a research-based biopharmaceutical company with products in immunology, neuroscience, oncology, eye care, aesthetics and other specialties. For the quarter ended March 31, 2026, it reported $15.002 billion of net revenue. Its official results reported $7.290 billion from immunology, $2.875 billion from neuroscience, $1.631 billion from oncology and $1.186 billion from aesthetics.
Medicines that treat autoimmune disease, cancer, neurological illness, eye disease, pain and other serious conditions serve clear human needs. That beneficial purpose is important qualitative evidence and should not be deleted merely because one financial ratio fails. It also does not make every product, formulation, research input, indication or commercial practice automatically equivalent.
Current Financial Screening
The calculation below uses AbbVie's latest available Form 10-Q as of this review and links directly to the official filing at the SEC. Balance-sheet inputs are dated March 31, 2026, and revenue and interest income use the matching three-month period.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-12.
72,858 / 136,463
9,421 / 136,463
21,870 / 136,463
72 / 15,002
- Financial
- Fails
- Overall
- Fails
Debt is 53.39% of total assets and exceeds the 33.333% limit. Identifiable liquidity is 6.90%, receivables plus cash is 16.03%, and disclosed gross interest income is 0.48%; those ratios pass, but the debt failure determines the financial result.
- Financial
- Fails
- Overall
- Fails
Debt is 53.39% and exceeds the examined 33.33% total-assets limit. Liquidity and receivables-plus-cash pass, but the debt failure determines the result; the product- and use-level business screen remains incomplete.
- Financial
- Fails
- Overall
- Fails
Debt is 53.39% and exceeds the examined 33% total-assets limit. This is a calculation against the SAC ratios, not an official SAC classification of a U.S.-listed security; screened product revenue is unavailable.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible 24- or 36-month issuer market-cap history is not yet stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
AbbVie researches, develops and commercializes medicines and products across immunology, neuroscience, oncology, eye care, aesthetics and other specialties. Treating serious disease, reducing pain and improving health are generally beneficial and permissible purposes. Medical and aesthetic products still require product- and use-specific review rather than assuming every formulation, input and indication is identical.
Limitation: The filing provides detailed product revenue but does not classify revenue by Sharia-screened formulation, excipient, alcohol carrier, animal-derived or biologic input, cell line, research method, manufacturing process, licensing arrangement, clinical use, or elective aesthetic use. No exact prohibited-revenue percentage can be reproduced from consolidated disclosure.
Purification
Disclosed gross interest income equals 0.48% of quarterly net revenues. Product- and use-level screened operating revenue remains unavailable, so 0.48% is evidence for the income screen rather than a complete fixed purification prescription.
Inputs, assumptions and primary sources
- Interest-bearing debt is the sum of zero short-term borrowings, 8,326 of the current portion of long-term debt and 64,532 of long-term debt using the reported balance-sheet carrying amounts.
- Cash and equivalents use the reported 9,391 balance.
- Identifiable interest-bearing securities are 10 of money-market funds and time deposits plus 20 of debt securities. Public and non-readily-determinable equity securities are excluded from the liquidity numerator.
- Receivables use the reported 12,479 net accounts-receivable balance.
- Net revenues of 15,002 and disclosed gross interest income of 72 use the same three-month period ended March 31, 2026.
- AbbVie discloses revenue by product and therapeutic portfolio, but not as a Sharia-screened numerator by formulation, excipient, biologic input, cell line, research method, manufacturing input, licensing arrangement, clinical use, or aesthetic use.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
What the Numbers Show
AbbVie reported no short-term borrowings, $8.326 billion as the current portion of long-term debt and $64.532 billion of long-term debt. Together, $72.858 billion of interest-bearing debt equals 53.39% of $136.463 billion of total assets. That exceeds the 33.333%, 33.33% and 33% total-assets limits examined here.
Cash plus identifiable interest-bearing securities is 6.90% of assets, while net accounts receivable plus cash is 16.03%; those ratios pass. The securities input includes $10 million of money-market funds and time deposits plus $20 million of debt securities. Equity securities are excluded rather than being mislabeled as interest-bearing instruments.
Market-cap methodologies can produce a different result because they use a historical average market-value denominator. ZakatInvest does not estimate those methods from a current share price; they remain not calculated until a reproducible and properly licensed 24- or 36-month history is stored.
Ingredients, Biologics and Manufacturing
A pharmaceutical company cannot be screened responsibly by assuming every medicine contains the same inputs. Product-specific active ingredients, excipients, alcohol carriers, animal-derived materials, biologic inputs, cell lines and manufacturing processes may matter under a chosen standard. AbbVie's consolidated filing reports revenue by product but does not provide a Sharia-screened classification for those inputs.
This evidence gap does not prove that AbbVie's portfolio is prohibited. It means a precise prohibited-revenue percentage cannot be reproduced from the filing. Investors with formulation-specific requirements should consult current prescribing information, manufacturer evidence and qualified medical and Sharia expertise for the relevant product and indication.
Animal Research and Alternatives
The original asset record correctly kept animal-derived research concerns visible. AbbVie's animal-research policy states that animals are used when viable alternatives cannot provide required data and describes a program based on replacement, reduction and refinement. It also identifies cell-based assays, organ-on-chip systems, artificial tissues, modeling and other alternatives.
A qualitative review should examine necessity, welfare safeguards, oversight, contractor standards and whether validated alternatives are adopted promptly. A policy statement is relevant evidence of governance, but it is not a substitute for evaluating actual research practices and outcomes.
Safety, Clinical Trials and Responsible Promotion
Pharmaceutical benefit must be considered with potential harm. Investors may assess efficacy, adverse events, pharmacovigilance, manufacturing quality, supply continuity, trial design, informed consent, participant diversity, data transparency, medical-device cybersecurity and post-market safety. Marketing should communicate evidence and risk accurately rather than encouraging unnecessary treatment or inappropriate prescribing.
Pricing, Patents and Patient Access
Pricing, affordability, insurance access, patents, exclusivity, biosimilar competition and availability in lower-income markets are central justice questions. AbbVie describes country-specific patient support and a U.S. assistance program that can provide qualifying patients with medicine at no cost. Those programs are meaningful, while broader pricing, access barriers and the distribution of benefits and burdens still require independent assessment.
Aesthetics and Use-Specific Ethics
AbbVie's aesthetics portfolio includes Botox Cosmetic and Juvederm. Some aesthetic products also have therapeutic or reconstructive uses, while elective use can raise different questions involving medical necessity, alteration of appearance, body-image pressure, informed consent, safety and marketing. Consolidated revenue does not separate uses according to a Sharia-screened framework, so the analysis preserves this nuance rather than assigning one ruling to every procedure.
Dividend and Purification
AbbVie's official dividend history shows a $1.73 quarterly dividend in 2026, or $6.92 annualized if that rate continues. The live yield changes with the share price and is intentionally not hard-coded.
Gross interest income was $72 million, equal to 0.48% of quarterly revenue. This passes the examined income limit, but product- and use-level screened operating revenue is unavailable. ZakatInvest therefore presents 0.48% as evidence for the income screen, not as a complete fixed purification instruction.
Bottom Line
ABBV is doubtful in ZakatInvest's canonical classification. Its medicines and research have substantial potential benefit, which remains part of the qualitative analysis. Its current total-assets financial screens nevertheless fail because debt is 53.39% of assets, while product formulations, research inputs, licensing, aesthetics uses and a complete purification numerator require further evidence. This is a screening classification, not a fatwa or investment recommendation; apply your chosen methodology with a qualified Sharia adviser for a binding ruling.
Use our free halal checker to review ABBV and thousands of other assets.
Open Halal Checker →